Patients with PD-L1 + NSCLC were enrolled in the phase 2 clinical study (CITYSCAPE) to compare the anti-TIGIT antibody tiragolumab with atezolizumab versus placebo plus atezolizumab. Here, CD274 is linked to non-small cell lung carcinoma.